Viridian Therapeutics (NASDAQ:VRDN) Releases Quarterly Earnings Results, Beats Estimates By $0.24 EPS

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24, Zacks reports. The firm had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%.

Viridian Therapeutics Price Performance

Shares of Viridian Therapeutics stock traded down $1.12 during trading on Monday, hitting $14.41. 1,219,704 shares of the stock traded hands, compared to its average volume of 1,179,288. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -3.34 and a beta of 1.32. The firm's fifty day moving average is $18.10 and its 200-day moving average is $19.70. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20.

Analyst Upgrades and Downgrades

VRDN has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. TD Cowen initiated coverage on Viridian Therapeutics in a report on Monday, November 25th. They set a "buy" rating on the stock. Royal Bank of Canada increased their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a report on Tuesday, December 17th. Needham & Company LLC reissued a "buy" rating and set a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Finally, Wells Fargo & Company reissued an "equal weight" rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Viridian Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.